Scott Hecker

Dr. Hecker has over 30 years of industry experience in leading medicinal chemistry and manufacturing in antibiotic drug discovery and development. He began his industrial career at Pfizer as a medicinal chemist in antibacterial drug discovery and then joined Microcide/Essential Therapeutics, where he led teams in the discovery of novel anti-infective drug candidates. He then moved to Metabasis Therapeutics where he oversaw the discovery and early development of drug candidates for diabetes, hyperlipidemia, and hepatitis C in programs that advanced in development under partnerships with Merck and Roche. He later joined Mpex/Rempex Pharmaceuticals, where he was a founding member of the beta-lactamase inhibitor program that discovered the now FDA-approved agent vaborbactam, and continued at the Medicines Company following the acquisition of Rempex to oversee the API manufacturing and early discovery programs. Dr. Hecker has over 40 publications and over 55 U.S. patents. He holds a B.A. in Chemistry from Wesleyan University and a Ph.D. in Chemistry from the University of California, Berkeley.